The Yes-associated protein 1 (YAP1), a major downstream effector of the Hippo pathway, functions as a transcriptional regulator and has an important role in cellular control of organ size and tumor growth. Elevated oncogenic activity of YAP1 has been clarified in different types of human cancers, which contributes to cancer cell survival and chemoresistance. However, the molecular mechanism of YAP1 overexpression in cancer is still not clear. Here we demonstrate that the deubiquitination enzyme USP9X deubiquitinates and stabilizes YAP1, thereby promoting cancer cell survival. Increased USP9X expression correlates with increased YAP1 protein in human breast cancer cell lines and patient samples. Moreover, depletion of USP9X increases YAP1 polyubiquitination, which in turn elevates YAP1 turnover and cell sensitivity to chemotherapy. Overall, our study establishes the USP9X-YAP1 axis as an important regulatory mechanism of breast cancer and provides a rationale for potential therapeutic interventions in the treatment of breast cancer.
Introduction
The Hippo/Yes-associated protein 1 (YAP1) signaling pathway is one of the most important factors in organ size regulation and tissue homeostasis. The misregulation of Hippo/YAP1 pathway is involved in cancer development [1] [2] [3] . As a transcriptional co-activator, YAP1 does not contain any DNA-binding domains, which elicits its transcription activation via interaction with other transcription factors including TEA domain (TEAD) transcription factor family members SMAD2, β-catenin, and Runt-related transcription factor 2, to promote proliferation and tumor growth [2, [4] [5] [6] [7] .
The activity of YAP1 is tightly regulated at physiological conditions, where elevated YAP1 activity and/or overexpression has been observed in different cancer types [3] . In humans, the kinase cascade MST1/2-Lats1/2 functions to inactivate YAP1 by directly phosphorylating YAP1 at Ser 127, which consequently results in cytoplasmic retention of phosphorylated YAP1 via binding to 14-3-3 [8, 9] . Conversely, dephosphorylated YAP1 localizes to the nucleus, which in turn induces gene expression that promotes cell proliferation and organ growth [10, 11] . Recently, several labs have shown that cellular energy stress induces LKB1/ AMPK-dependent activation of Hippo pathway kinase cascades, which subsequently phosphorylates and These authors contributed equally: Lei Li, Tongzheng Liu inactivates YAP1 [12] [13] [14] [15] . Moreover, AMPK directly phosphorylates YAP1 and abolishes the YAP1-TEAD interaction [12, 13] . c-Abl also phosphorylates YAP1 at the Y357 site following DNA damage, which in turn enhances YAP1 binding to p73 and activates p73-regulated proapoptotic target gene expression [16] . In addition, the tyrosine kinase YES1 phosphorylates YAP1 and triggers the HEK293T cells were lysed and IPed with indicated antibodies. The immunocomplexes were subjected to western blotting. c MDA-MB-231 cells stably expressing control (ctrl) or USP9X shRNAs were subjected to western blot and qRT-PCR to examine the indicated protein and mRNA level. Lower panel: YAP1 mRNA level relative to β-actin was quantified (mean ± SD (n = 6)). d Cells as in c were left untreated or treated with MG-132 and western blotting was performed to examine the indicated protein levels. e CHX pulse-chase assay was performed in cells as in c. Right panel: the protein levels of YAP1 relative to β-actin (mean ± SEM of three independent experiments) localization of the YAP1-TBX5-β-catenin complex to the promoters of anti-apoptotic genes [4] .
In addition to the regulatory mechanisms controlling its phosphorylation and localization, YAP1 can be regulated by other posttranslational modification. YAP1 is coordinately phosphorylated by Lats and CK1, and this phosphorylation regulates YAP1 ubiquitination and degradation through the E3 ubiquitin ligase β-TRCP [17] . A recent study reported that Fbxw7 regulates YAP1 stability through ubiquitin-proteasomal degradation in hepatocellular carcinoma [18] . However, the mechanisms governing YAP1 protein stability in human cancers remain largely unknown. Thus, the identification of the signaling pathway controlling YAP1 stabilization will be important to demostrate the biological function of YAP1 and can be exploited for potential therapeutic interventions.
Here we report that USP9X regulates breast cancer cell proliferation and cancer cell response to therapeutic drugs through the YAP1 pathway. Mechanistically, USP9X deubiquitinates and stabilizes YAP1. In addition, depletion of USP9X decreases breast cancer proliferation, tumorigenesis, and chemoresistance in a YAP1-dependent manner. Furthermore, USP9X overexpression is observed in breast cancers, which is correlated with the high expression of YAP1, suggesting that the USP9X-YAP1 axis may have a role in the pathogenesis of breast cancers.
Results

USP9X is a bona fide DUB targeting YAP1 protein for deubiquitination and stabilization
Previous studies showed that YAP1 ubiquitination and degradation were mediated by several E3 ligases, such as β-TRCP and Fbxw7. However, the process of YAP1 deubiquitination is still unclear. Multiple proteomic databases showed USP9X in YAP1 purification complex. (https://www.ncbi.nlm.nih.gov/gene/10413) and (http://www.genecards.org/cgi-bin/carddisp.pl?gene= YAP1&keywords=yap1). Therefore, we first tested the interaction between USP9X and YAP1. We found that endogenous USP9X coimmunoprecipitated with endogenous YAP1 in the co-immunoprecipitation experiment ( Fig. 1a, b ). The interaction of USP9X and YAP1 led us to test a potential role for the deubiquitination enzyme USP9X in the regulation of YAP1 turnover and function. We found overexpression of wild-type (WT) USP9X but not the catalytic inactive mutant (CS mutant) in MDA-MB-231 cells dramatically increased YAP1 protein level (Supplementary Figure 1A) . Conversely, depletion of USP9X in MDA-MB-231 cells significantly decreased YAP1 protein level but did not affect YAP1 mRNA level ( Fig. 1c ). Depletion of USP9X in ovarian cancer cell line OVCAR8 also downregulated YAP1 protein levels (Supplementary Figure 1B) . In addition, treating cells with the proteasome inhibitor, MG132, rescued the decreased YAP1 protein level in cells depleted of USP9X ( Fig. 1d ). Previous studies showed that USP9X deubiquitinates MCL1 and promotes cancer cell survival in human follicular lymphoma and diffuse large B-cell lymphoma [19] . We observed a moderate decrease in MCL1 protein level in USP9X-depleted cells ( Supplementary Figure 1D ). Moreover, USP9X was reported to target Angiomotin (AMOT) and AMOT-like 2 (AMOTL2), which in turn regulates YAP1 activation [20, 21] . However, in our study, depletion of USP9X did not affect AMOT levels ( Fig.  1d and Supplementary Figure 1B -C). We then hypothesized that USP9X may regulate YAP1 stability. Indeed, YAP1 protein was less stable after USP9X knockdown ( Fig. 1e ). Moreover, overexpression of USP9X dramatically increased YAP1 stabilization (Supplementary Figure 1E ), whereas overexpression of the CS mutant decreased YAP1 stability. Taken together, these results suggest that USP9X directly regulates YAP1 stability.
To further investigate whether USP9X functions as a DUB for YAP1 protein, we performed a deubiquitination assay by co-transfecting cells with WT USP9X or the CS mutant in the presence of MG132. A significant decrease in polyubiquitylated YAP1 protein was observed in cells transfected with WT USP9X, whereas the expression of CS mutant was not able to decrease YAP1 ubiquitination ( Fig.  2a ). On the other hand, depletion of USP9X significantly increased YAP1 ubiquitination (Fig. 2b ). In addition, the USP9X inhibitor WP1130 [22] significantly enhanced YAP1 ubiquitination ( Fig. 2c ). Furthermore, USP9X removed K48linked polyubiquitination of YAP1 (Supplementary Figure  2A) . Taken together, these results suggest that USP9X is a DUB that regulates YAP1 deubiquitination and stability.
USP9X regulates cell proliferation through YAP1
To assess the effect of USP9X on YAP1 transactivation, we utilized a YAP1-dependent luciferase reporter system, which consists of a 5xUAS-luciferase reporter and a Gal4 DNA-binding domain fused to TEAD4 (Gal4-TEAD4) [9] . The reporter activity was strongly suppressed in cells stably expressing USP9X or YAP1 short hairpin RNA (shRNA) (Fig. 3a ). Depletion of USP9X in cells depleted of YAP1 had no further inhibitory effect on reporter activity, indicating that USP9X suppresses the reporter activity mainly through YAP1 (Fig. 3a ). In addition, we examined the YAP1-regulated gene transcripts (CTGF, CYR61, and ANKRD1) and found depletion of USP9X dramatically decreased the transcripts of CTGF, CYR61, and ANKRD1 in control cells but not in YAP1 knockdown cells (Fig. 3b ). These results suggested that USP9X regulates YAP1dependent transcription. As a key effector of the Hippo signaling pathway, YAP1 regulates organ size and tumor growth by modulating cell proliferation. Next, we investigated potential functions of USP9X in cancer cell proliferation and anchorage-independent cancer cell growth. Depletion of USP9X led to decreased cell proliferation ( Fig.  3c ), whereas depletion of both USP9X and YAP1 did not cause a further decrease in cell proliferation compared with cells depleted of YAP1 alone. Similar effects were observed in colony-formation assays (Fig. 3d ). Taken together, all these results suggest that USP9X regulates the proliferation of cancer cells in a YAP1-dependent manner. Next, we tested whether YAP1 is able to rescue the proliferation defect caused by USP9X depletion. As shown in Fig. 3e , depletion of USP9X caused a dramatic loss of colony forming ability, whereas the reconstitution of YAP1 was able to efficiently rescue this defect. On the other hand, overexpression of AMOT could not rescue cancer cell growth in USP9X-depleted cells (Supplementary Figure  3A) . Xenograft experiments further showed that depletion of USP9X or YAP1 similarly inhibited tumor growth, whereas the combined knockdown of USP9X and YAP1 did not further reduce tumor growth ( Fig. 3f ). This is consistent with in vitro results using cancer cell lines and indicates that USP9X affects tumor cell proliferation by regulating YAP1.
USP9X is positively correlated to YAP1 in clinical breast cancer samples
As YAP1 has a key role in human cancer development, it is possible that USP9X promotes deubiquitination and stabilization of YAP1 in human cancers. We then examined the expression of USP9X and YAP1 in breast cancer cell lines and cancer tissue samples. As shown in Fig. 4a , USP9X is overexpressed in most of the breast cancer cell lines. Furthermore, high USP9X protein levels correlate with increased YAP1 in most of the breast cancer samples (Fig.  4b) . To further confirm the results, we performed immunohistochemical staining of USP9X and YAP1 in breast cancer tissue microarrays. As shown in Fig. 4c,d , both USP9X and YAP1 are overexpressed in breast carcinoma compared with normal breast tissues. Furthermore, USP9X positively correlated with YAP1 expression level but not with MCL1 or AMOT level in breast carcinoma ( Fig. 4d and Supplementary Figure 4A-B) . Taken together, these results indicate that USP9X is upregulated in breast carcinoma, positively correlating with YAP1 expression. Fig. 3 USP9X regulates cell proliferation and anchorage-independent growth through YAP1. a MDA-MB-231 cells were transfected with indicated constructs with the luciferase reporter constructs. The YAP1 activity was analyzed by the luciferase reporter assay (mean ± SD (n = 6)). b YAP-regulated gene transcripts were detected by qRT-PCR in MDA-MB-231 cells stably expressing indicated shRNAs. The data were normalized to the β-actin mRNA (mean ± SD (n = 3)). c Cell proliferation of the cells generated as in b was measured by MTS assay (mean ± SEM of three independent experiments). d The cells were generated as in b and colony-formation assays were performed (mean ± SEM of three independent experiments). e Cells stably expressing ctrl or USP9X shRNAs together with or without FLAG-YAP1. Cells were cultured in soft agar and cell growth was measured (mean ± SEM of three independent experiments). f Cells generated as in a were injected into immunodeficient mice as described in Methods. Tumor growth was measured every 3 days (mean ± SD of 5 mice). All of the statistical analyses were performed with the ANOVA. *p < 0.05; **p < 0.01. ***p < 0.001
USP9X regulates response of breast cancer cells to chemotherapy through YAP1
The activation of transcriptional coactivator YAP1 has been shown to have a role in chemoresistance in different malignancies such as ovarian cancer, melanoma, and hepatocellular carcinoma. Considering that YAP1 is stabilized by USP9X, we tested whether inhibition of USP9X activity by its pharmacological inhibitor or specific shRNA affects cell response to chemotherapy. First, cells were treated with vehicle or USP9X inhibitor WP1130, and the responses to mitomycin C (MMC), cisplatin, and etoposide were subsequently measured. We found that the USP9X inhibitor WP1130 promoted YAP1 degradation (Fig. 5a ). In addition, WP1130 sensitized cells to chemotherapy (Fig.  5b) , whereas cells reconstituted with FLAG-YAP1 were significantly resistant to chemotherapy even in the presence of WP1130. Similarly, depletion of USP9X in cells using two specific shRNAs significantly decreased YAP1 protein levels ( Fig. 5c ) and increased cellular sensitivity to MMC, cisplatin, and etoposide ( Fig. 5d ), while reconstituting USP9X-depleted cells with FLAG-YAP1 reversed hypersensitivity to chemotherapy (Fig. 5d ). These results establish an important role of USP9X in regulating chemotherapeutic response, at least in part through YAP1.
In summary, we demonstrate that USP9X interacts with YAP1 and promotes its deubiquitination, ultimately leading to YAP1 stabilization (Fig. 5e ). We reveal USP9X as a positive regulator of YAP1 in breast cancer cell proliferation and a potential biomarker for predicting chemoresistance.
Discussion
YAP1, a major factor of the Hippo tumor suppressor pathway, is known to have significant roles in multiple cellular processes, such as cell proliferation, differentiation, [2, [23] [24] [25] [26] [27] [28] [29] . YAP1 has been reported both as a tumor suppressor and an oncogene [8, 30] . A previous study reported that low YAP1 levels prevent nuclear ABL1-mediated apoptosis in hematologic malignancies, whereas restored YAP1 levels by genetic inactivation of STK4 triggers cell death in vitro and in vivo [31] . In addition, YAP1 can be directly phosphorylated by c-Abl following DNA damage, which in turn facilitates YAP1 binding to p73 and co-activates p73-dependent pro-apoptotic target genes [16] . In contrast, YAP1 was also reported to function as a potent oncogene and is associated with the prognosis of many human cancers including prostate, breast, ovarian, and hepatocellular cancers [3, 8, 15, 32] . Several recent studies have elucidated that two different E3 ubiquitin ligases (SCFβ-TrCP and SCFFbw7) control YAP1 ubiquitination and degradation. A DUB protein, DUB3, controls the protein stability of multiple components of Hippo pathway including the E3 ligase ITCH, the LATS kinases, and the AMOT family of proteins, which in turn induces YAP1 turnover [33] . Moreover, previous studies showed that USP9X targets AMOT and AMOTL2, which in turn regulates YAP1 activation [20, 21] . However, in our study, depletion of USP9X did not affect AMOT levels in both breast and ovarian cancer cell lines ( Fig. 1d and Supplementary Figure 1B-C) . Although we can not completely exclude the possibility that USP9X regulates Amot in other cancer models, such as the regulation of Amot by USP9X in clear cell renal cell carcinoma (ccRCC) model [20] . However, deubiquitinases that directly mediate and oppose YAP1 ubiquitination has not been identified yet. Fig. 5 USP9X regulates the breast cancer cells response to chemotherapy. a MDA-MB-231 cells were stably expressed with the indicated constructs and treated with either vehicle or USP9X inhibitor WP1130 for 12 h. The cells were subjected to western blot to examine the indicated protein levels. b Cells as in a were treated with MMC, cisplatin, and etoposide, and cell survival was determined (mean ± SD (n = 6)). c T47D cells stably expressing ctrl or USP9X shRNA together with or without FLAG-YAP1 were subjected to western blotting to examine the indicated protein levels. d Cells as in c were treated with MMC, cisplatin, and etoposide, and cell survival was determined (mean ± SD (n = 6)). e The experimental model of how USP9X regulates YAP1
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The deubiquitination enzymes are proteases that remove ubiquitin chains from diverse substrates and regulate multiple cellular processes, such as cell survival, cell differentiation, chromosome remodeling, as well as apoptosis [19, [34] [35] [36] [37] . Similar to YAP1, the biological effects of USP9X in human cancers are complex, which could be regulated by different proteins targeted by USP9X in different cellular context. In pancreatic ductal adenocarcinoma, USP9X was reported to be a tumor suppressor, in which USP9X is the most commonly mutated gene and was inactivated in more than half of the tumors [38] . USP9X has also been reported to regulate cellular sensitivity to chemo and radiotherapies. USP9X deubiquitinates and stabilizes MCL1 in distinct human cancers including human follicular lymphomas, diffuse large B-cell lymphomas, glioblastoma, colon, and lung cancers [19] . The USP9X inhibitor WP1130 or depletion of USP9X by its specific shRNAs induces MCL-1 degradation in cells and increases tumor cell sensitivity to chemo and radiotherapies [39] . On the other hand, a recent study showed that USP9X regulates cell survival and radio-sensitivity without affecting MCL-1 protein level in Jurkat cells and several glioblastoma cell lines, indicating MCL-1-independent mechanisms [40] . Thus, identifying novel substrates other than MCL-1 is essential for understanding USP9X biology and its implication in tumorigenesis and drug resistance.
Here we reveal a connection between USP9X and the Hippo-YAP pathway in breast cancer. In this study, we demonstrate that USP9X may target YAP1 for deubiquitination and stabilization, thereby promoting breast cancer growth and tumor progression. Anti-cancer effects of USP9X inhibition could be partially reversed by restoring YAP1 expression in vitro and in vivo. Interestingly, USP9X was positively correlated to YAP1 protein expression in breast cancers. Our study provides evidence of USP9X-YAP1 as a potential biomarker for predicting chemoresistance in breast cancers. In addition, targeting the USP9X-YAP1 axis could be used to sensitize cancer cells to radio and chemotherapy, although clinical effect of USP9X/ YAP1 inhibitors needs to be further tested. Furthermore, although our study mostly focused on Paclitaxel and breast cancers, our finding that USP9X-YAP1 axis affects the response to chemotherapeutic agents would have broader implications for the treatment of other cancers and should be examined in the future.
Materials and Methods
Cell culture, constructs, and antibodies
We purchased mammary epithelial cell line MCF10A and breast cancer cell lines MDA-MB-231, HCC-1806, MDA-MB-468, BT549, MCF7, T47D, AU565, Hs578T, BT474, and HCC-1824 from ATCC. OVCAR8 and HEK 293T cells were also purchased from ATCC. All the cell lines have tested and confirmed by the Mayo Clinic medical genome facility center. USP9X WT and its inactive mutants were purchased from MRC PPU (University of Dundee). The luciferase reporter constructs were kindly provided by Guan and colleagues [9] . YAP1 cDNA was kindly provided by Chen and colleagues [11] , and we subcloned it to pCMV-HA and pLV.3-FLAG vectors.
Anti-USP9X (catalog number: 55054-1-AP) antibody was purchased from Proteintech. Anti-p-YAP1 (4911S) antibody was purchased from Cell Signaling. Anti-YAP1 (SC15407) and anti-Ub (sc-8017) antibodies were purchased from Santa Cruz. Antibodies against HA (H9658), FLAG (F1804), β-actin (A1978), and β-Tubulin (T8328) were purchased from Sigma.
RNA interference
USP9X shRNAs were kindly provided by Drs William G. Kaelin and Qing Zhang [36] : USP9xsh#1, 5′-GGTCGTTACAGCTAGTATTTA-3′; USP9xsh#2, 5′-CGCCTGATTCTTCCAATGAAA-3′; USP9xsh#3, 5′-CGACCCTAAACGTAGACATTA-3′; USP9xsh#4, 5′-GAGAGTTTATTCACTGTCTTA-3′. YAP1 shRNAs were purchased from Sigma (NM_006106.3-1354s21c1). We generated the lentiviruses for USP9X and YAP1 shRNAs according to the standard protocol.
Deubiquitination assay in vivo
HEK293T cells transfected with HA-YAP1, FLAG-USP9X, and Myc-Ub as indicated were incubated with 25 μM MG132. After 4 h incubation, the cells were carefully washed twice with pre-chilled phosphate-buffered saline and then collected. Then the cells were lysed in 120 μl buffer with 10% glycerol, 2% SDS pH 6.8 Tris-HCl (62.5 mM), 1 mM iodoacetamide, and 20 mM NEM. Next, the cell lysates were boiled for 15 min and then diluted with NETN lysis buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.5% Nonidet P-40) containing protease inhibitors and deubiquitination inhibitors in 1 : 10 ratio. After 20 min, the cell lysates were IPed with indicated antibodies and protein A/G beads for 4 h (4°C). After washing the beads, the immunocomplexes were subjected to western blotting.
Cell survival assay
The breast cancer cell lines stably expressing the indicated constructs were treated with MMC, cisplatin, or etoposide at indicated concentrations. After 72 h, the plates were read in an Epoch2 microplate reader (BioTek Instruments). The cell survival ratio was examined by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay (Promega).
Soft agar colony-formation assays
The breast cancer cells (MDA-MB-231) stably expressing ctrl or USP9X shRNA together with FLAG-YAP1 were plated in 0.3% (w/v) agarose with a base layer of 0.6% (w/ v) agarose. Both of the layers contained the complete medium. After 2 weeks, colonies were counted by using a light microscope with 4 × numerical aperture 0.10 objective lens (ECLIPSE 80i; Nikon).
Tumor growth study in xenograft
MDA-MB-231 cells stably expressing the control; USP9X, YAP1, or USP9X together with YAP1 shRNAs were injected subcutaneously into female athymic nu/nu mice (NCI) mammary fat pad (10 6 cells/mouse) by randomization. Every 3 days, the tumor volumes were measured following standard protocol. Data were analyzed using analysis of variance (ANOVA) test. By following the blinding procedures, two persons as a study group performed all the mice experiments. Dr Lei Li injected the cells into the mice and Dr Yunhui Li, who is totally blinded to the experiment group, measured the tumor and analyzed the data. The experimental protocol was approved by the IACUC at Mayo Clinic.
Mice were subjected to killing when the following situations happened: displaying pain or distress, such as weight loss (> 10% of body weight), not eating or drinking, lethargy, lying down, or difficulty in breathing.
Immunohistochemical staining
The tissue microarray was purchased from Biomax (BR1101, BR1002 and BC08022).The immunohistochemical staining and quantification were described previously [41] . The immunostaining was blindly scored by pathologists. The IHC score was calculated as described previously [42] . The χ 2 -test and the Pearson's correlation coefficient were used for statistical analysis of the correlation between USP9X and YAP1.
Statistical analysis
Data are represented as the mean ± SEM of three independent experiments for cell proliferation and soft agar assays. Data are represented as the mean ± SD (n = 6) for cell survival assay. Data are represented as the mean ± SD of five mice for the tumor growth study in xenograft. The Student's t-test, ANOVA, and χ 2 -test were utilized for the statistical analyses (*p < 0.05; **p < 0.01; ***p < 0.001).
